Skip to main content
search

Plaque Psoriasis

Hightower Clinical conducted a pediatric clinical trial to assess the safety and tolerability of an investigational drug in children with mild to moderate plaque psoriasis.

                       

Contributed to Advancing Pediatric Psoriasis Care

Plaque psoriasis (psoriasis vulgaris) is the most common form of psoriasis, affecting around 6.7 million adults. It causes thick, scaly, discolored patches—called plaques—on the skin, commonly appearing on the elbows, knees, back, and scalp. In severe cases, it can affect the face, hands, feet, genitals, and legs. These plaques can be itchy, painful, or feel like burning.

Hightower Clinical conducted a clinical study to evaluate the safety and tolerability of a study drug in children aged 6 to 17 with mild to moderate plaque psoriasis, aiming to expand effective care options for pediatric patients.

Current Status

Not Recruiting

Study Count

01

Study Information

Plaque Psoriasis

Study NameProtocol NumberSponsor
Plaque Psoriasis

20200196

Amgen

Frequently Asked Questions

1. What was the purpose of this plaque psoriasis clinical trial?

The study aimed to evaluate the safety and tolerability of a study drug in children aged 6 to 17 with mild to moderate plaque psoriasis.

2. Who was eligible to participate in the study?

Pediatric patients between the ages of 6 and 17 years who are diagnosed with mild to moderate plaque psoriasis.

3. Is the plaque psoriasis clinical trial currently open?

No, the study is currently not recruiting participants.

Close Menu